"For consumers, the bottom line is simple: If a product claims to work 'just like a GLP-1 drug,' promises dramatic weight loss, or minimizes risk with slogans like 'all the benefits without the discomfort,' that should be a red flag," Ventura says
Semaglutide reduces A1C by approximately 1.5% to 1.8% while producing significant weight loss
It also increases the likelihood of non-infectious gastroenteritis, gastroparesis, hypotension, sleep disturbances, arthralgia, interstitial nephritis, and tendinitis
That changed when the SURMOUNT-5 trial compared tirzepatide (the active ingredient in Zepbound) and semaglutide directly
Learn more $50 off your first month of Alloy Weight Care for new customers